No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
Here's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
Cynata Therapeutics Concludes Patient Enrolment in Diabetic Foot Ulcer Wound Dressing Product Trial
Cynata Therapeutics Receives EU Approval for CYP-001 Phase 2 Trial
Cynata Therapeutics' Breakthrough in Regenerative Medicine
Cynata Therapeutics Doses First Patient in Phase Two Trial of Cellular Therapy; Shares Rise 5%
Cynata Therapeutics Names Chief Business Officer; Shares Plunge 14%
No Data